Sugi Predict

Sugi Predict / Compounds / SCHEMBL1486796

SCHEMBL1486796

SCHEMBL1486796

O=C(O)C(Cc1ccc(O)cc1)N(Cc1ccccc1)P(=O)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.45
▸ SLC7A5 Q01650 2/20 0.44
▸ FNTA P49354 1/20 0.42
▸ FNTB P49356 1/20 0.42
▸ TRPV1 Q8NER1 1/20 0.42
▸ MME P08473 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ ESR1 P03372 1/20 0.40
▸ TAS2R14 Q9NYV8 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ BCHE P06276 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALPI P09923 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ XIAP P98170 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27799946 0.82 SLC7A5 (0.49) POLBSLC7A5FNTAFNTBTRPV1
SCHEMBL28215882 0.80 CA12 (0.42) POLBSLC7A5CYP1A2CA12CA9
SCHEMBL28059546 0.79 SLC7A5 (0.46) POLBSLC7A5FNTAFNTBTRPV1
SCHEMBL28059544 0.79 SLC7A5 (0.46) POLBSLC7A5FNTAFNTBTRPV1
SCHEMBL1486797 0.79 ANPEP (0.48) POLBSLC7A5FNTAFNTBTRPV1
SCHEMBL1486794 0.79 ANPEP (0.48) POLBSLC7A5FNTAFNTBTRPV1
SCHEMBL8588545 0.76 SLC7A5 (0.49) POLBSLC7A5TRPV1ESR1
SCHEMBL20856984 0.75 FNTA (0.47) POLBSLC7A5FNTAFNTBTRPV1
SCHEMBL607090 0.75 SLC7A5 (0.55) POLBSLC7A5FNTAFNTBESR1
SCHEMBL9754096 0.75 SLC7A5 (0.55) POLBSLC7A5FNTAFNTBESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 — — EP disclosed
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-02-13 — — US disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 — — EP disclosed
US-20240294596-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-09-05 — — US disclosed
WO-2024151615-A1 MRNA DISPLAY LIBRARIES AND METHODS OF USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-07-18 — — WO disclosed
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2023-10-05 — — US disclosed
EP-4210729-A2 INSULIN RECEPTOR PARTIAL AGONISTS Merck Sharp & Dohme LLC (US) 2023-07-19 — — EP disclosed
EP-3660041-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2023-04-19 — — EP disclosed
US-11351268-B2 FGF21 C-terminal peptide optimization INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2022-06-07 — — US disclosed
WO-2022055877-A2 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-03-17 — — WO disclosed
WO-2016049190-A1 INCRETIN-INSULIN CONJUGATES INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-03-31 — — WO disclosed
EP-2793932-A1 CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES Indiana University Research and Technology Corporation (US) 2014-10-29 — — EP disclosed
WO-2013096386-A1 CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2013-06-27 — — WO disclosed
EP-2443146-A1 GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS Indiana University Research And Technology Corporation (US) 2012-04-25 — — EP disclosed
WO-2011163473-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-12-29 — — WO disclosed
EP-2307037-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS Indiana University Research and Technology Corporation (US) 2011-04-13 — — EP disclosed
EP-2300037-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS Indiana University Research and Technology Corporation (US) 2011-03-30 — — EP disclosed
WO-2010148089-A1 GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-12-23 — — WO disclosed
WO-2009155257-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 — — WO disclosed
WO-2009155258-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11351268-B2 FGF21 C-terminal peptide optimization FGF23, FGFR1, FGFR3 POLB 4372/4885SLC7A5 2004/4885FNTA 1046/4885
US-20240294596-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 POLB 3593/4885SLC7A5 1241/4885FNTA 2739/4885
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 POLB 3593/4885SLC7A5 1241/4885FNTA 2739/4885
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 POLB 3593/4885SLC7A5 1241/4885FNTA 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.